3-AP 50 mg | 99.05%
TargetMol
3-AP (Triapine) is a novel inhibitor of the M2 subunit of ribonucleotide reductase (RR).
More Information Supplier Page3-AP
Search Results
3-AP 25 mg | 99.05%
TargetMol
3-AP (Triapine) is a novel inhibitor of the M2 subunit of ribonucleotide reductase (RR).
More Information Supplier Page3-AP
3-AP 10 mg | 99.05%
TargetMol
3-AP (Triapine) is a novel inhibitor of the M2 subunit of ribonucleotide reductase (RR).
More Information Supplier Page3-AP
Cinaciguat 5 mg | Purity Not Available
TargetMol
Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in Clinicalal development for acute decompensated heart failure.
More Information Supplier PageCinaciguat
Defactinib 100 mg | 99.80%
TargetMol
Defactinib is an orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities.
More Information Supplier PageDefactinib
Ponalrestat 5 mg | 98.05%
TargetMol
Ponalrestat
Ponalrestat 50 mg | 98.05%
TargetMol
Ponalrestat
Ponalrestat 10 mg | 98.05%
TargetMol
Ponalrestat
Defactinib 5 mg | 99.80%
TargetMol
Defactinib is an orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities.
More Information Supplier PageDefactinib
Defactinib 50 mg | 99.80%
TargetMol
Defactinib is an orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities.
More Information Supplier PageDefactinib